Media Centre
Our latest news and
announcements.
Mayo Clinic Magazine Highlights C the Signs’ Impact on Early Cancer Diagnosis
.webp)
Mayo Clinic
We’re proud to share that Mayo Clinic Magazine has published an in-depth feature on C the Signs, spotlighting our journey, scientific breakthroughs, and mission to transform how cancer is diagnosed - globally.
Recognition from one of the world’s most respected medical institutions marks a new chapter in our mission to drive earlier detection, better outcomes, and a future where no patient is diagnosed too late.
A Story That Resonates
The feature, titled “C the Signs: Building digital solutions to find cancer up to five years sooner,” takes readers inside the origins and innovation behind our platform.
It begins with the story of Dr Bea Bakshi, who, after witnessing a patient’s late pancreatic cancer diagnosis during her time as an NHS doctor, was driven to ask a single question:
“What if we could help doctors spot the earliest signs of cancer - before it’s too late?”
From that question came the foundation for C the Signs - and the start of a new approach to early diagnosis.
The Mayo Clinic piece explores:
- How our AI models have been developed to detect patterns across multiple tumour types
- Our “closed-loop learning” system, which continuously refines itself with every patient interaction
- And our collaboration with Mayo Clinic’s Platform_Accelerate programme, enabling retrospective validation against diverse US patient datasets
One of the most powerful findings: in retrospective analysis, C the Signs identified cancers up to five years earlier in 26% of patients across the five highest-mortality cancer types - breast, colorectal, lung, prostate, and pancreatic.
That kind of lead time doesn’t just change statistics.
It changes lives. As our Co-Founder and CEO, Bea shared with Mayo Clinic:
“We’ve detected over 65,000 patients with cancer in the UK. In five years’ time, I want to be talking about the number of patient lives we’ve saved in the United States.”
Defying Time. Rewriting the Possible.
Our collaboration with Mayo Clinic reflects the next phase of our mission - building a future where early detection is standard for all, not a privilege for some.
Every earlier diagnosis is a life changed.
And every life changed redefines what’s possible.
-
Photography by Lincoln Gore / Mayo Clinic
A Year of Impact: Reflections on 2024 from Dr Bea Bakshi, CEO of C the Signs
As 2024 draws to a close, it feels like the right moment to pause and reflect on what has been an extraordinary year for C the Signs - a year defined by our relentless pursuit of purpose and our shared mission to ensure that no patient faces a late cancer diagnosis.
This has been a year of measurable progress, meaningful partnerships, and, most importantly, real impact.
Transforming Lives Through Early Detection
In 2024, we reached remarkable milestones - completing over 400,000 cancer risk assessments and identifying more than 30,000 patients with cancer across 50+ cancer types.
Each number represents more than data. It represents a person whose cancer was found earlier, a family given more time, and a future rewritten.
These achievements bring us one step closer to our vision:
A world where every patient survives cancer.
Driving Research and Global Recognition
This year, our research was recognised on some of the world’s most influential scientific stages.
- At the ASCO General Meeting in Chicago, we shared findings demonstrating improved early cancer detection rates - without increasing healthcare utilisation.
- At the Early Detection of Cancer Conference in San Francisco, our data showed a 50% improvement in diagnostic speed.
- At the European Cancer Summit in Brussels, we presented evidence of significant stage shift in ovarian cancer, detecting cases earlier than ever before.
- And most recently, at the San Antonio Breast Cancer Symposium, we revealed breakthrough findings showing C the Signs identified women at risk of breast cancer up to five years earlier than physicians, in 20% of cases, with accuracy comparable to mammography.
Each of these studies reinforces the same truth:
When cancer is found earlier, lives can be transformed.
Our Defining Value: Impact
When I asked our team what single value defines C the Signs, one word came through clearly - impact.
That word guides every decision we make, every partnership we build, and every innovation we create.
It is the heartbeat of who we are - a team united by the belief that technology can restore something medicine too often loses: time.
Gratitude and Collaboration
None of this would be possible without the people who make our mission real.
To our exceptional team - your dedication, brilliance, and compassion inspire me every day.
To the clinicians we partner with across the NHS and beyond - thank you for your trust, courage, and unwavering commitment to your patients, often in the most challenging circumstances.
Together, we are proving that early detection isn’t just possible - it’s happening.
Looking Ahead to 2025
As we look to the year ahead, our mission remains as clear as ever:
to accelerate earlier cancer detection and to ensure every patient, everywhere, has access to the care they need, when they need it.
2025 will bring new challenges - but also new opportunities to scale our impact, deepen our partnerships, and expand the boundaries of what’s possible in early diagnosis.
From all of us at C the Signs, thank you for being part of this journey.
Wishing everyone a joyful holiday season and a bright New Year filled with hope, innovation, and lives transformed.
Defy time. Rewrite the possible.
—
Dr Bea Bakshi
Co-Founder & CEO, C the Signs
.webp)
C the Signs Selected by the White House CancerX Accelerator
C the Signs has been selected as part of the inaugural White House CancerX Accelerator, a major U.S. initiative uniting global leaders in oncology, technology, and innovation to deliver on President Biden’s Cancer Moonshot vision - to reduce cancer mortality by 50% over the next 25 years.
This marks an extraordinary moment for C the Signs - and for the UK’s role in global healthcare innovation - as the only British company chosen among the 16 organisations forming the first CancerX Accelerator cohort.
Transforming Early Diagnosis on a Global Stage
Built within the NHS and founded by UK doctors, C the Signs is redefining how cancer is detected.
The platform uses artificial intelligence to help clinicians identify patients at risk of cancer at the earliest and most treatable stage.
So far, the system has:
- Identified over 25,000 patients with cancer,
- Achieved 98% accuracy in identifying risk, and
- Supported clinicians across 1,500+ GP practices in finding cancer faster and earlier.
Through the CancerX Accelerator, C the Signs joins forces with leading organisations including AstraZeneca, Intel, Dell Technologies, AWS, and UC Davis Health - forming part of a global collaboration dedicated to transforming the future of cancer care.
“A Pivotal Moment to Lead with Heart”
“As a doctor, I am deeply moved and profoundly grateful for our selection to participate in the inaugural CancerX Accelerator,” said Dr Bea Bakshi, CEO and Co-Founder of C the Signs.
“At C the Signs, our mission is rooted in the belief that early detection can change the course of this disease - aiming for a future where surviving cancer is the norm, not the exception. This is more than an opportunity; it’s a pivotal moment to lead with heart and create meaningful change.”
Recognising UK Leadership in Health Innovation
“This recognition is a testament to the UK’s leadership in healthcare innovation and our capacity to create technology solutions with a global impact,” said Aphrodite Spanou, Director of Healthcare UK at the Department of Health and Social Care, NHS England, and the Department for Business and Trade.
“C the Signs’ work in early cancer detection not only exemplifies British ingenuity but also demonstrates how local innovation can achieve international significance.”
Bringing Together AI and Oncology to Rewrite the Possible
The CancerX Accelerator provides a unique opportunity for cross-sector collaboration - connecting C the Signs with cancer experts, research networks, and innovation partners across the United States.
This partnership represents more than recognition; it’s the next step in scaling early cancer detection globally, combining UK clinical excellence with international innovation to help save lives worldwide.
About C the Signs
Founded by NHS doctors Dr Bea Bakshi and Dr Miles Payling, C the Signs is an AI-powered clinical platform that enables healthcare professionals to identify patients at risk of cancer earlier, faster, and more accurately.
Validated through peer-reviewed research and partnerships with NHS England, Health Innovation Networks, and now the White House CancerX Accelerator, C the Signs continues to redefine what’s possible in early cancer detection - giving people back time, choice, and life.
📢 Read more about the White House CancerX Accelerator: https://cancerx.health/accelerator
🌐 Learn more about C the Signs: www.cthesigns.com
C the Signs Ranked 3rd In BusinessCloud’s MedTech 50
Recognised as One of the UK’s Leading HealthTech Innovators
We’re honoured to announce that C the Signs has been ranked 3rd in BusinessCloud’s MedTech 50, the annual ranking that celebrates the most innovative medical technology creators, developers, and adopters in the UK.
This recognition highlights the impact of our mission - using AI to detect cancer earlier and save lives - and reflects the growing importance of technology in transforming how healthcare is delivered.
Celebrating Innovation in MedTech
The MedTech 50 list, supported by digital transformation experts Sputnik Digital, recognises UK companies that are revolutionising medicine, patient care, and clinical outcomes through technology.
This year’s finalists were chosen through a combination of public votes and independent judging, drawing almost 800 votes from across the sector.
The judging panel included:
- Avi Mehra, Co-founder and Managing Director, Doctorpreneurs
- Leontina Postelnicu, Head of Health and Social Care, techUK
- Abeyna Bubbers-Jones, CEO, Medic Footprints
- Jonathan Symcox, Editor, BusinessCloud
We’re incredibly proud to have been recognised alongside so many inspiring organisations driving innovation in healthcare.
Recognition That Fuels Our Mission
Awards like this represent more than recognition — they’re a reminder of why we do what we do.
Every vote and every mention helps raise awareness for our mission to create a world where everyone survives cancer.
“We’re truly grateful to everyone who voted for us and to BusinessCloud for this honour. Recognition like this pushes our mission forward - using technology to give people back time, choice, and life.”
- Dr Bea Bakshi, CEO and Co-Founder of C the Signs.
About BusinessCloud’s MedTech 50
BusinessCloud’s Tech 50 series showcases the most promising companies transforming key sectors through digital innovation.
The MedTech 50 specifically spotlights those reshaping healthcare — from AI-driven diagnostics to digital health records and next-generation patient tools.
You can view the full 2022 MedTech 50 ranking on BusinessCloud’s website:
👉 Read the full list on BusinessCloud →
About C the Signs
C the Signs is an AI-powered clinical platform that helps healthcare professionals identify patients at risk of cancer earlier, faster, and more accurately.
Founded by NHS doctors Dr Bea Bakshi and Dr Miles Payling, the platform supports clinicians across the UK and internationally — detecting a patient with cancer every 22 minutes.
Featured
Cancer in Numbers: Why Interception Matters with Dr Miles Payling
Dr. Miles Payling
At the inaugural C the Signs Conference, Dr Miles Payling - Co-Founder and Chief Scientific Officer - delivered a message that captured the spirit of the movement redefining how the world detects cancer.
In a talk that fused science with humanity, he spoke not only about technology, but about time and how every second counts in the journey to early diagnosis.
“We can’t afford to wait for symptoms to become obvious. Every moment matters - because every moment lost is a choice, a treatment, a life that could have been saved.”
The Why - Where It All Began
Miles began with the story that shaped C the Signs’ mission. As an NHS doctor, he met a patient named Joe - fit, active, and 60 years old. After several GP visits with vague symptoms, Joe arrived at A&E jaundiced and weak. Scans confirmed metastatic pancreatic cancer. Three weeks later, Joe died.
“Joe never asked, why do I have cancer? What he asked was, why was my cancer picked up so late?”
That single question became the foundation of C the Signs - a platform designed to detect cancer early enough to change the outcome .
Today, that vision saves time and lives - with a patient with cancer detected every 22 minutes.
Why Early Detection Still Fails Too Many
Cancer remains the leading cause of death in the UK, with survival determined by the stage at diagnosis.
For breast cancer, five-year survival is 97.9 % at stage 1 but just 26.2 % at stage 4.
For bowel cancer, it falls from 91.7 % to 10.3 % .
Yet only 58.7 % of patients are diagnosed at early stages .
In primary care - where 90 % of all NHS patient contact takes place - GPs face impossible pressures: 10-minute consultations, thousands of patients, and on average just eight new cancer diagnoses a year .
“The problem isn’t people. It’s knowledge. We need to give every GP the power of precision - instantly.”
The Innovation - Redefining What’s Possible
C the Signs is an AI-powered, pan-cancer platform integrated directly with electronic health records. In under 30 seconds, it assesses risk, predicts tumour origin, and guides clinicians to the right diagnostic pathway across 100+ cancer types.
Real-world evaluations across the NHS have shown:
- 99 % sensitivity - finding nearly all patients with cancer
- 99 % negative predictive value - safely ruling out risk
- 94 % accuracy in predicting tumour origin
- 50 % reduction in emergency cancer presentations
- 21 % faster time-to-diagnosis - from 85 days to 67 days
Each figure represents a human life identified earlier, a family spared uncertainty, and a system made stronger.
The Movement - Honouring Jess’s Rule
Miles closed his speech by reflecting on Jessica Brady’s story - a 27-year-old whose symptoms were missed, leading to a late diagnosis and preventable loss .
To honour her legacy, C the Signs is implementing “Jess’s Rule” - a feature that automatically alerts clinicians when a patient presents three times or more with unresolved symptoms, and triggers a cancer risk assessment .
“We can turn tragedy into transformation - by ensuring that no patient is ever overlooked again.”
Together, we can make early cancer detection a standard for all, not a privilege for some - and give every person the time they deserve.
Publicity
Mayo Clinic Magazine Highlights C the Signs’ Impact on Early Cancer Diagnosis
We’re proud to share that Mayo Clinic Magazine has published an in-depth feature on C the Signs, spotlighting our journey, scientific breakthroughs, and mission to transform how cancer is diagnosed - globally.
Recognition from one of the world’s most respected medical institutions marks a new chapter in our mission to drive earlier detection, better outcomes, and a future where no patient is diagnosed too late.
A Story That Resonates
The feature, titled “C the Signs: Building digital solutions to find cancer up to five years sooner,” takes readers inside the origins and innovation behind our platform.
It begins with the story of Dr Bea Bakshi, who, after witnessing a patient’s late pancreatic cancer diagnosis during her time as an NHS doctor, was driven to ask a single question:
“What if we could help doctors spot the earliest signs of cancer - before it’s too late?”
From that question came the foundation for C the Signs - and the start of a new approach to early diagnosis.
The Mayo Clinic piece explores:
- How our AI models have been developed to detect patterns across multiple tumour types
- Our “closed-loop learning” system, which continuously refines itself with every patient interaction
- And our collaboration with Mayo Clinic’s Platform_Accelerate programme, enabling retrospective validation against diverse US patient datasets
One of the most powerful findings: in retrospective analysis, C the Signs identified cancers up to five years earlier in 26% of patients across the five highest-mortality cancer types - breast, colorectal, lung, prostate, and pancreatic.
That kind of lead time doesn’t just change statistics.
It changes lives. As our Co-Founder and CEO, Bea shared with Mayo Clinic:
“We’ve detected over 65,000 patients with cancer in the UK. In five years’ time, I want to be talking about the number of patient lives we’ve saved in the United States.”
Defying Time. Rewriting the Possible.
Our collaboration with Mayo Clinic reflects the next phase of our mission - building a future where early detection is standard for all, not a privilege for some.
Every earlier diagnosis is a life changed.
And every life changed redefines what’s possible.
-
Photography by Lincoln Gore / Mayo Clinic
A Year of Impact: Reflections on 2024 from Dr Bea Bakshi, CEO of C the Signs
As 2024 draws to a close, it feels like the right moment to pause and reflect on what has been an extraordinary year for C the Signs - a year defined by our relentless pursuit of purpose and our shared mission to ensure that no patient faces a late cancer diagnosis.
This has been a year of measurable progress, meaningful partnerships, and, most importantly, real impact.
Transforming Lives Through Early Detection
In 2024, we reached remarkable milestones - completing over 400,000 cancer risk assessments and identifying more than 30,000 patients with cancer across 50+ cancer types.
Each number represents more than data. It represents a person whose cancer was found earlier, a family given more time, and a future rewritten.
These achievements bring us one step closer to our vision:
A world where every patient survives cancer.
Driving Research and Global Recognition
This year, our research was recognised on some of the world’s most influential scientific stages.
- At the ASCO General Meeting in Chicago, we shared findings demonstrating improved early cancer detection rates - without increasing healthcare utilisation.
- At the Early Detection of Cancer Conference in San Francisco, our data showed a 50% improvement in diagnostic speed.
- At the European Cancer Summit in Brussels, we presented evidence of significant stage shift in ovarian cancer, detecting cases earlier than ever before.
- And most recently, at the San Antonio Breast Cancer Symposium, we revealed breakthrough findings showing C the Signs identified women at risk of breast cancer up to five years earlier than physicians, in 20% of cases, with accuracy comparable to mammography.
Each of these studies reinforces the same truth:
When cancer is found earlier, lives can be transformed.
Our Defining Value: Impact
When I asked our team what single value defines C the Signs, one word came through clearly - impact.
That word guides every decision we make, every partnership we build, and every innovation we create.
It is the heartbeat of who we are - a team united by the belief that technology can restore something medicine too often loses: time.
Gratitude and Collaboration
None of this would be possible without the people who make our mission real.
To our exceptional team - your dedication, brilliance, and compassion inspire me every day.
To the clinicians we partner with across the NHS and beyond - thank you for your trust, courage, and unwavering commitment to your patients, often in the most challenging circumstances.
Together, we are proving that early detection isn’t just possible - it’s happening.
Looking Ahead to 2025
As we look to the year ahead, our mission remains as clear as ever:
to accelerate earlier cancer detection and to ensure every patient, everywhere, has access to the care they need, when they need it.
2025 will bring new challenges - but also new opportunities to scale our impact, deepen our partnerships, and expand the boundaries of what’s possible in early diagnosis.
From all of us at C the Signs, thank you for being part of this journey.
Wishing everyone a joyful holiday season and a bright New Year filled with hope, innovation, and lives transformed.
Defy time. Rewrite the possible.
—
Dr Bea Bakshi
Co-Founder & CEO, C the Signs
C the Signs Selected by the White House CancerX Accelerator
C the Signs has been selected as part of the inaugural White House CancerX Accelerator, a major U.S. initiative uniting global leaders in oncology, technology, and innovation to deliver on President Biden’s Cancer Moonshot vision - to reduce cancer mortality by 50% over the next 25 years.
This marks an extraordinary moment for C the Signs - and for the UK’s role in global healthcare innovation - as the only British company chosen among the 16 organisations forming the first CancerX Accelerator cohort.
Transforming Early Diagnosis on a Global Stage
Built within the NHS and founded by UK doctors, C the Signs is redefining how cancer is detected.
The platform uses artificial intelligence to help clinicians identify patients at risk of cancer at the earliest and most treatable stage.
So far, the system has:
- Identified over 25,000 patients with cancer,
- Achieved 98% accuracy in identifying risk, and
- Supported clinicians across 1,500+ GP practices in finding cancer faster and earlier.
Through the CancerX Accelerator, C the Signs joins forces with leading organisations including AstraZeneca, Intel, Dell Technologies, AWS, and UC Davis Health - forming part of a global collaboration dedicated to transforming the future of cancer care.
“A Pivotal Moment to Lead with Heart”
“As a doctor, I am deeply moved and profoundly grateful for our selection to participate in the inaugural CancerX Accelerator,” said Dr Bea Bakshi, CEO and Co-Founder of C the Signs.
“At C the Signs, our mission is rooted in the belief that early detection can change the course of this disease - aiming for a future where surviving cancer is the norm, not the exception. This is more than an opportunity; it’s a pivotal moment to lead with heart and create meaningful change.”
Recognising UK Leadership in Health Innovation
“This recognition is a testament to the UK’s leadership in healthcare innovation and our capacity to create technology solutions with a global impact,” said Aphrodite Spanou, Director of Healthcare UK at the Department of Health and Social Care, NHS England, and the Department for Business and Trade.
“C the Signs’ work in early cancer detection not only exemplifies British ingenuity but also demonstrates how local innovation can achieve international significance.”
Bringing Together AI and Oncology to Rewrite the Possible
The CancerX Accelerator provides a unique opportunity for cross-sector collaboration - connecting C the Signs with cancer experts, research networks, and innovation partners across the United States.
This partnership represents more than recognition; it’s the next step in scaling early cancer detection globally, combining UK clinical excellence with international innovation to help save lives worldwide.
About C the Signs
Founded by NHS doctors Dr Bea Bakshi and Dr Miles Payling, C the Signs is an AI-powered clinical platform that enables healthcare professionals to identify patients at risk of cancer earlier, faster, and more accurately.
Validated through peer-reviewed research and partnerships with NHS England, Health Innovation Networks, and now the White House CancerX Accelerator, C the Signs continues to redefine what’s possible in early cancer detection - giving people back time, choice, and life.
📢 Read more about the White House CancerX Accelerator: https://cancerx.health/accelerator
🌐 Learn more about C the Signs: www.cthesigns.com
C the Signs Ranked 3rd In BusinessCloud’s MedTech 50
Recognised as One of the UK’s Leading HealthTech Innovators
We’re honoured to announce that C the Signs has been ranked 3rd in BusinessCloud’s MedTech 50, the annual ranking that celebrates the most innovative medical technology creators, developers, and adopters in the UK.
This recognition highlights the impact of our mission - using AI to detect cancer earlier and save lives - and reflects the growing importance of technology in transforming how healthcare is delivered.
Celebrating Innovation in MedTech
The MedTech 50 list, supported by digital transformation experts Sputnik Digital, recognises UK companies that are revolutionising medicine, patient care, and clinical outcomes through technology.
This year’s finalists were chosen through a combination of public votes and independent judging, drawing almost 800 votes from across the sector.
The judging panel included:
- Avi Mehra, Co-founder and Managing Director, Doctorpreneurs
- Leontina Postelnicu, Head of Health and Social Care, techUK
- Abeyna Bubbers-Jones, CEO, Medic Footprints
- Jonathan Symcox, Editor, BusinessCloud
We’re incredibly proud to have been recognised alongside so many inspiring organisations driving innovation in healthcare.
Recognition That Fuels Our Mission
Awards like this represent more than recognition — they’re a reminder of why we do what we do.
Every vote and every mention helps raise awareness for our mission to create a world where everyone survives cancer.
“We’re truly grateful to everyone who voted for us and to BusinessCloud for this honour. Recognition like this pushes our mission forward - using technology to give people back time, choice, and life.”
- Dr Bea Bakshi, CEO and Co-Founder of C the Signs.
About BusinessCloud’s MedTech 50
BusinessCloud’s Tech 50 series showcases the most promising companies transforming key sectors through digital innovation.
The MedTech 50 specifically spotlights those reshaping healthcare — from AI-driven diagnostics to digital health records and next-generation patient tools.
You can view the full 2022 MedTech 50 ranking on BusinessCloud’s website:
👉 Read the full list on BusinessCloud →
About C the Signs
C the Signs is an AI-powered clinical platform that helps healthcare professionals identify patients at risk of cancer earlier, faster, and more accurately.
Founded by NHS doctors Dr Bea Bakshi and Dr Miles Payling, the platform supports clinicians across the UK and internationally — detecting a patient with cancer every 22 minutes.